Skip to main content
. 2007 Aug 31;65(2):265–269. doi: 10.1111/j.1365-2125.2007.03017.x

Table 2.

Identified risk factors for reporting prescribed drugs upon admission

Model 1 OR (95% CI) Model 2 OR (95% CI)
Number of reimbursements**
    One reimbursement 0.22 (0.13, 0.35)**
    Two to four reimbursements 0.62 (0.4, 0.98)*
    ≥5 reimbursements 1
ATC group**
    Dermatologicals (ATC D) 0.04 (0.02, 0.12)** 0.05 (0.01, 0.16)**
    Anti-infectives (ATC J) 0.11 (0.06, 0.17)** 0.15 (0.08, 0.26)**
    Musculoskeletal (ATC M) 0.17 (0.09, 0.36)** 0.18 (0.09, 0.35)**
    Sensory (ATC S) 0.23 (0.08, 0.66)* 0.23 (0.08, 0.64)**
    Respiratory (ATC R) 0.35 (0.19, 0.62)** 0.30 (0.17, 0.53)**
    Alimentary tract (ATC A) 0.38 (0.20, 0.72)** 0.35 (0.18, 0.66)**
    Genitourinary (ATC G) 0.49 (0.18, 1.29) 0.37 (0.14, 0.96)*
    Nervous (ATC N) 0.47 (0.27, 0.82)* 0.40 (0.32, 0.69)**
    Hormones (ATC H) 0.46 (0.08, 2.60) 0.48 (0.08, 2.70)
    Blood (ATC B) 0.51 (0.21, 1.24) 0.48 (0.20, 1.14)
    Cardiovascular (ATC C) 1 1
Sex NS NS
Age NS NS

Results from the multiple logistic regression analysis reported as odds ratios (OR). Model 1 only includes Anatomical Therapeutic Chemical (ATC) group as explanatory variable. Model 2 includes ATC group and the number of reimbursements as explanatory variables. Calculations are corrected for patient's sex and age, although these variables were without statistical significance.

Prescribed drugs were identified as drugs registered in pharmacy records 0–30 days before admission.

Number of reimbursements during the 6 months preceding admission.

*

P < 0.05;

**

P < 0.005.